Forecasted · Cooperative Agreement
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2
National Institutes of Health, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2
- Issuing agency
- National Institutes of Health (Department of Health and Human Services)
- Opportunity number
- RFA-DA-28-001
- Funding type
- Cooperative Agreement
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close June 8, 2027 (agency estimate)
- Agency estimates
- Estimated posting: February 1, 2027. Estimated award date: April 1, 2028. Estimates can change.
- Published award range
- Up to $1,000,000
- Estimated total program funding
- $5,000,000
- Expected number of awards
- 8
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.279
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/363680 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 363680 · Funding opportunity number RFA-DA-28-001
- Posted
- August 20, 2026 · Source last updated August 20, 2026
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 100% of key fields published by the source
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Eligibility details (from the agency)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
Description (from the official listing)
NIDA seeks to further advance its mission in the area of single cell biology. Since 2020, the NIDA-funded Single Cell Opioid Responses in the Context of HIV (SCORCH) consortium has generated single-nucleus datasets from human and animal postmortem brain tissue under conditions of HIV infection, antiretroviral therapy (ART), and/or substance exposure (e.g. opioids, cocaine, methamphetamine, and cannabinoids). Building on this Phase 1 foundation, NIDA will encourage research addressing critical questions on Substance Use Disorder (SUD) and interactions with HIV disease progression at the subcellular, cellular, or circuit levels in the Central Nervous System (CNS). Many new cutting-edge single cell approaches (e.g. interrogation of RNA splicing, non-coding RNAs, epigenomic or proteomic features, subcellular or synaptic localization and function, spatial interactions, cell-cell communication, or cellular connectivity) now enable novel hypothesis-generating studies. Along with data mining studies to identify candidate mechanisms or targets contributing to HIV/SUD interactions and hypothesis-driven studies to assess functional significance, we expect SCORCH Phase 2 to significantly advance our mechanistic understanding of SUDs and HIV in the CNS and identify targets for novel therapies. Grant authorities that allow NIDA to forecast this opportunity are 42 U.S.C. §§ 241 and 284
Agency contact
National Institute on Drug Abuse (NIDA)
NIDA_GED_Program@nida.nih.gov